Thursday, October 15, 2026

AI Tools Erode Active Fund Manager Edge as $11 Trillion Passive Shift Accelerates

Veteran fund manager Guy Spier says AI has eliminated the research advantage that powered Buffett-style stock-picking, as machine learning now replicates months of analysis in hours. Vanguard passive ETFs carry Strong Buy ratings with 40%+ upside while active managers charging 1-2% fees struggle to justify costs across global markets.

LM Salvado
LM Salvado

March 30, 2026

AI Tools Erode Active Fund Manager Edge as $11 Trillion Passive Shift Accelerates
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Guy Spier, founder of Aquamarine Fund, says artificial intelligence has ended the era of Buffett-and-Munger-style stock-picking as machine learning tools eliminate the research edge active managers once held worldwide.1

"The probability that I'll outperform has reduced even more," Spier states, noting AI streamlines fundamental research that previously required months of analyst work across multiple markets.1 Natural language processing now parses earnings calls in English, Mandarin, and dozens of languages simultaneously, while alternative data sets once exclusive to elite funds have become commoditized globally.

The shift accelerates a $11 trillion migration to passive strategies that began in U.S. markets and now spans Europe and Asia. Vanguard S&P 500 Growth ETF holds a Strong Buy rating with over 40% upside potential, while comparable active funds charging 1-2% management fees face mounting pressure to justify costs.1

AI-driven screening compresses time advantages across global bourses. High-frequency algorithms and quantitative funds deploying machine learning dominate short-term mispricings from New York to Tokyo, leaving traditional stock-pickers competing for shrinking opportunities. "It's grown increasingly difficult to identify overlooked corners of the market," Spier adds.1

The competitive erosion hits hardest in developed markets where data transparency and algorithmic trading are most advanced. European active managers face similar pressures as UCITS funds compete with low-cost index trackers, while Asian markets see rapid adoption of quant strategies by institutional investors.

For institutional allocators managing pension funds and sovereign wealth pools, the math grows stark. Index-tracking strategies deliver comparable returns at a fraction of active management costs, with Vanguard S&P 500 ETF carrying a Moderate Buy rating with 31% upside.1 As AI narrows valuation gaps faster than human analysts exploit them, stock return dispersions tighten globally.

Spier's acknowledgment that AI has "streamlined the painstaking research once viewed as a key advantage" signals a structural inflection point.1 If veteran value investors concede disadvantage, capital rotation from active to passive allocations could intensify across global asset management.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com